Clinical Research Directory

Inclusion Criteria: * Patients with histologically confirmed localized prostate cancer who are planned for CT- or MRI-adaptive SBRT for prostate cancer; * Presence of PIRADS ≥3 lesion(s) in a mpMRI correlating with Gleason ≥7 score at diagnosis; * Intermediate to (very) high risk localized prostate cancer (≤ cT3b and cN0); * ECOG performance status of 0-2; * Age ≥ 18 years; * PSMA PET ≤3 months is compulsory for high-risk prostate cancer (as part of clinical routine); * Written informed consent. * Willingness and ability to comply with schedule Exclusion Criteria: * Previous (≤10 years) local therapy of the prostate including transurethral resection of the prostate (TURP), * Contraindication for MRI; * Previous (≤10 years) radiotherapy in the pelvis; * Lymph node metastases or distant metastases (i.e. no localized prostate cancer); * Participation in a clinical trial which might influence the results of this project; * Claustrophobic anxiety; * Uncontrolled intercurrent illness; * Relation to investigator (family or professional)